flow trial semaglutide all-cause mortality hazard ratio Relative risk of each individual MACE component as a function of CV Contrary to popular belief: GLP-1

Efficacy and safety In clinical trials, patients taking retatrutide have shown an average weight loss reduction of up to 24% from baseline body weight

[4] Dietary approaches that support metabolic health include adequate protein intake (which has a higher thermic effect than carbohydrates or fats), sufficient fibre consumption, and avoiding ultra-processed foods

[Localization of glutathione-S-transferase in transparent and cataractous research-subject lenses]

Retatrutide, an investigational triple agonist that adds glucagon receptor activation, now points toward what may be the next benchmark

The main reason is this

Using FDA-approved therapies like tirzepatide and semaglutide with close medical supervision, patients achieve meaningful, sustained weight loss and improved metabolic health